Literature DB >> 3527075

Chemotherapy-induced acral erythema in patients receiving bone marrow transplantation.

M K Crider, J Jansen, A L Norins, M S McHale.   

Abstract

Chemotherapy-induced acral erythema is an uncommon and distinctive syndrome of intense macular erythema of the palms and fingers seen in patients treated with high-dose chemotherapy. It is painful, may form bullae, and heals uneventfully with desquamation. The incidence (35%) of this complication in patients receiving bone marrow transplantation at our institution is quite high and probably reflects the exceptional doses of chemotherapy and concomitant total body irradiation these patients receive. Biopsy specimens showed vacuolar change, spongiosis, necrotic keratinocytes, and epidermal atypia. These findings probably result from direct toxic effect and mimic those of acute graft-vs-host disease. Awareness of chemotherapy-induced acral erythema is important to avoid its misdiagnosis as a cutaneous sign of acute graft-vs-host disease. This distinction can usually be made on clinical grounds. If necessary, serial skin biopsy specimens are helpful.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3527075

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  2 in total

1.  Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.

Authors:  Nilofer S Azad; Jeanny B Aragon-Ching; William L Dahut; Martin Gutierrez; William D Figg; Lokesh Jain; Seth M Steinberg; Maria L Turner; Elise C Kohn; Heidi H Kong
Journal:  Clin Cancer Res       Date:  2009-02-15       Impact factor: 12.531

2.  Vascular endothelial growth factor (VEGF) antibody significantly increases the risk of hand-foot skin reaction to multikinase inhibitors (MKIs): A systematic literature review and meta-analysis.

Authors:  Yi Zhu; Xiaochen Zhang; Xiaoe Lou; Min Chen; Peihua Luo; Qiaojun He
Journal:  Clin Exp Pharmacol Physiol       Date:  2018-04-25       Impact factor: 2.557

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.